Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 10/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028589 | 0.90 | BCL9 (0.54) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL4033307 | 0.90 | BCL9 (0.54) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL4028580 | 0.90 | BCL9 (0.54) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL4030825 | 0.88 | BCL9 (0.54) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL6193937 | 0.87 | BCL9 (0.50) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL6193930 | 0.87 | BCL9 (0.50) | BCL9CTNNB1PDE4BLIPGPROKR1 | |
| SCHEMBL4034468 | 0.83 | BCL9 (0.51) | BCL9CTNNB1PDE4BPROKR1CETP | |
| SCHEMBL4034464 | 0.83 | BCL9 (0.51) | BCL9CTNNB1PDE4BPROKR1CETP | |
| SCHEMBL4968602 | 0.82 | PDE4B (0.55) | BCL9CTNNB1PDE4BMEN1KMT2A | |
| SCHEMBL4029545 | 0.81 | BCL9 (0.47) | BCL9CTNNB1PDE4BPROKR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| CN-100439337-C | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-20070281935-A1 | Use | PFIZER INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1765320-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | Pfizer Products Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1753426-A2 | RUMINANT TREATMENTS | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1717389-A | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2006-01-04 | — | — | CN | disclosed |
| WO-2005115389-A2 | SPECIFIC PPAR AGONISTS FOR TREATING NEGATIVE ENERGY BALANCE | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115369-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885 |
| US-20070281935-A1 | Use | ALPP, CPT1A, PIGS | BCL9 3385/4885CTNNB1 995/4885PDE4B 4165/4885 |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | PPARG, PPARD, PPARA | BCL9 3397/4885CTNNB1 1557/4885PDE4B 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.